tipifarnib has been researched along with cyclin d1 in 1 studies
| Studies (tipifarnib) | Trials (tipifarnib) | Recent Studies (post-2010) (tipifarnib) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 309 | 92 | 94 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Detre, S; Dowsett, M; Head, JE; Howes, A; Johnston, SR; Kaye, S; Martin, LA; Pancholi, S; Quinn, E; Salter, J | 1 |
1 other study(ies) available for tipifarnib and cyclin d1
| Article | Year |
|---|---|
The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Drug Therapy, Combination; Farnesyltranstransferase; Female; Flow Cytometry; Fluorescent Antibody Technique; G1 Phase; Humans; In Situ Nick-End Labeling; Mice; Mice, Nude; Quinolones; Receptors, Estrogen; Tamoxifen; Transcription, Genetic; Transplantation, Heterologous | 2007 |